The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | OBP101JP: final results of oncolytic virotherapy + suratadenoturev + RT for esophageal cancer
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the final results of the OBP101JP study, which investigated the use of oncolytic virotherapy with suratadenoturev (OBP-301) injection in combination with radiotherapy for patients with esophageal cancer. Dr Kato highlights that the trial demonstrated a significant increase in complete response rate, with 40% of patients achieving complete response compared to 20% with radiotherapy alone, resulting in improved quality of life for patients with limited treatment options. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
OBP101JP is an oncolytic virus. So that affects the telomerase or cancers. And then this drug was injected directly into the cancer cells. And then they work with a synergic effect with radiotherapy. So this drug was developed by Professor Fujiwara, Okayama University, and then Oncolys Biopharma developed and conducted the clinical trial for the esophageal cancer patient. The OBP101JP trial was conducted for mainly elderly patients with locally advanced esophageal cancer and the patients who are intolerant to chemotherapy receive radiotherapy only as a standard of care, but additionally, so local oncolytic virus injection, viral injection is not toxic and very feasible even for elderly patients...
OBP101JP is an oncolytic virus. So that affects the telomerase or cancers. And then this drug was injected directly into the cancer cells. And then they work with a synergic effect with radiotherapy. So this drug was developed by Professor Fujiwara, Okayama University, and then Oncolys Biopharma developed and conducted the clinical trial for the esophageal cancer patient. The OBP101JP trial was conducted for mainly elderly patients with locally advanced esophageal cancer and the patients who are intolerant to chemotherapy receive radiotherapy only as a standard of care, but additionally, so local oncolytic virus injection, viral injection is not toxic and very feasible even for elderly patients. This trial shows the additional effect of the oncolytic virus to radiation alone. And the complete response rate is 40%. And then, so our historical control of radiation alone for the same patients is just 20%. So we can see that 20% increase of the complete response rate, mainly in the primary site. And then the complete response is related to a better quality of life, and the patient can take food already more, and so we think this is so beneficial for patients who do not have so many options for treatment for esophageal cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
